|
Market Closed -
Nasdaq
21:30:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.300 USD | +1.56% |
|
-2.99% | -28.57% |
Company Valuation: Alzamend Neuro, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.273 | - |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 44.64% | - |
| Enterprise Value (EV) | 94.88 | 53.05 | 4.882 | 4.362 | 4.337 | 6.273 | 6.273 |
| Change | - | -44.08% | -90.8% | -10.66% | -0.56% | 44.64% | 0% |
| P/E | -7.29x | -3.65x | -0.48x | -0.52x | -0.43x | -1.24x | -1.49x |
| PBR | 7.3x | - | -1.85x | - | 6.62x | 32.5x | -2.06x |
| PEG | - | -0.51x | 0x | 0x | 0x | 0x | 0.1x |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -0.77x | -0.77x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.58x | -0.58x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -189 | -202.5 | -132.3 | -11.32 | -2.63 | -1.05 | -0.87 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA 1 | -7.907 | -11.26 | -8.931 | -4.121 | -7.949 | -8.2 | -8.2 |
| EBIT 1 | -12.32 | -14.87 | -9.938 | -4.497 | -8.767 | -10.8 | -10.8 |
| Net income 1 | -12.36 | -14.88 | -9.948 | -5.105 | -8.772 | -10.8 | -10.8 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 1,377.000 | 738.855 | 63.990 | 5.940 | 1.140 | 1.300 | 1.300 |
| Nbr of stocks (in thousands) | 68.9 | 71.8 | 76.3 | 734 | 3,805 | 4,826 | - |
| Announcement Date | 19/07/22 | 27/07/23 | 30/07/24 | 22/07/25 | 22/07/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.24x | - | - | - | 6.27M | |
| 18.77x | 6.69x | 13.41x | 1.58% | 65B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| 30.74x | 5.69x | 19.09x | -.--% | 22.5B | |
| Average | 23.37x | 26.57x | 15.32x | 0.32% | 37.24B | |
| Weighted average by Cap. | 25.97x | 25.01x | 15.48x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALZN Stock
- Valuation Alzamend Neuro, Inc.
Select your edition
All financial news and data tailored to specific country editions
